Preemie immune treatment to prevent lung infections and wheezing
Part of Women’s health & pregnancy clinical trials.
This study tests whether a bacterial “lysate” medicine, given to preterm babies, can reduce respiratory (lung) infections and wheezing. It may help protect babies’ airways during the vulnerable first months after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born between 30 weeks and 36 weeks of pregnancy (30+0 to 35+6).
- At the time of the study, your baby is at least 6 weeks old and has reached 37 weeks “post-menstrual age” (pregnancy age plus time since birth).
- You (both parents) or your baby’s formal caregiver can legally sign consent for the study.
- Your baby has not had a lower respiratory tract infection (a lung infection) before starting the study.
- Your baby is not under 2.5 kg (about 5.5 lbs) and was not described as having delayed maturity (“dysmaturity”) at randomization.
- There is no history of severe lung/heart/immune problems, and the baby is not known to be allergic to the study ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study supports children ages 2–6 who have been diagnosed with preschool wheeze and need regular lung follow-up. It checks a “next step” approach for managing symptoms in children who already use inhaler medicine and have had recent wheezing episodes.
This study looks at how the gut and lungs affect breathing problems in children. It compares samples from children with and without respiratory illnesses to understand why some children get sicker than others.
This study tests if giving oral steroids (medicine to reduce airway swelling) only when needed based on a child's own biology can help preschool children with wheezing. It aims to find the best treatment for each child, avoiding unnecessary medicine.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
This trial studies whether an early steroid treatment can lower the chance that children will go on to develop asthma after their first severe “wheezing” episode caused by a rhinovirus (a common cold virus). If you qualify, the goal is to prevent future asthma rather than just treat the current episode.
This trial tests a new treatment to help very premature babies (born at 22 to nearly 29 weeks) who still need a breathing machine and extra oxygen at 1–2 weeks old. The goal is to see if it can improve their lung health and reduce the need for breathing support.
Hear when a new Wheezing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.